The Form 4 filing, an SEC report of insider share activity, was filed on November 10, 2026. It covers purchases from November 6 through November 10.
The report lists Orbimed Advisors LLC as a director and 10% owner of Electra Therapeutics, Inc. (ETRA). The firm is the single insider covered by this report.
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-11-06 |
| Date of Latest Transaction | 2026-11-10 |
| Buy/Sell | buy |
| Transaction Count | 6 |
| Shares Transacted | 92,116 |
| Price | $8.08 |
| Total Transaction Value | $744,530.60 |
| Insider | |
| Ticker Symbol | ETRA |
| Company | Electra Therapeutics, Inc. |
| Insider Name | ORBIMED ADVISORS LLC |
| Insider Title | Director, 10% Owner |
| Sector - Industry | Other - Unclassified |
| Holdings | |
| Total Shares Owned After Transaction | 5,255,278 |
| Position Size Change | 1.75% |
| Filing | |
| Filing Date | 2026-11-10 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
These were purchases of company shares, reported under transaction code P. The six transactions were reported together in one filing.
What was the average price of the transaction?
The average purchase price was $8.08 per share, rounded to the nearest cent. This average covers all six purchases. Individual transaction prices were unavailable for this report.
How did this transaction affect the insider's holdings?
The firm bought 92,116 shares and reported owning 5,255,278 shares afterward. The newly bought shares made up 1.75% of its reported shares owned after the purchases.
What's the total transaction value?
The total transaction value was $744,530.60. That amount covers the 92,116 shares acquired across all six reported purchases.
Are there any special circumstances around this transaction?
The available transaction information did not identify a special arrangement. Filing footnote text was unavailable for this report, so any further terms or explanations remain unknown.
For research purposes only; not investment advice.